X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.fiercebiotech.com/biotech/fda-puts-curis-leukemia-trial-partial-hold-after-patient-death-spurs-review-muscle
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215066
https://www.globenewswire.com//news-release/2022/12/12/2572191/0/en/ORYZON-Presents-Final-Data-From-Phase-IIa-ALICE-Trial-in-Unfit-AML-Patients-with-First-line-Treatment-of-Iadademstat-and-Azacitidine-in-Oral-Presentation-at-ASH-2022.html
https://www.globenewswire.com//news-release/2022/12/12/2572030/0/en/ALX-Oncology-Announces-Initial-Data-from-ASPEN-05-Study-of-Evorpacept-in-Combination-with-Azacitidine-and-Venetoclax-Demonstrating-Tolerability-and-Preliminary-Activity-in-Patients.html
https://www.accesswire.com/731275/100-Clinical-Benefit-Rate-Achieved-in-Phase-1b-Trial-Evaluating-APVO436-in-Combination-with-Venetoclax-and-Azacitidine-for-Venetoclax-Treatment-Nave-Patients-with-Acute-Myeloid-Leukemia-AML
https://www.prnewswire.com/news-releases/innovent-presents-phase-1b-clinical-data-of-ibi188-anti-cd47-monoclonal-antibody-at-the-2022-american-society-of-hematology-annual-meeting-301699052.html
https://apnews.com/article/health-cancer-clinical-trials-8a62525c9b47e96447f4f108dfd42791
https://www.prnewswire.com/news-releases/i-mab-announces-approval-from-china-cde-to-initiate-phase-3-registrational-study-of-lemzoparlimab-in-combination-with-azacitidine-in-higher-risk-myelodysplastic-syndrome-301622810.html
https://www.prnewswire.com/news-releases/i-mab-announces-positive-phase-2-data-of-lemzoparlimab-in-combination-with-azacitidine-aza-in-patients-with-higher-risk-myelodysplastic-syndrome-at-esmo-2022-301621532.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-august-24-2022-1661335123.pdf
https://endpts.com/abbvie-calls-off-phi-trial-for-i-mabs-cd47-days-after-zai-lab-shelves-its-own-program/
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-august-17-2022-1660735823.pdf
https://www.globenewswire.com/news-release/2022/06/10/2460446/0/en/ORYZON-at-EHA-2022-Iadademstat-42-month-ALICE-Data-Demonstrate-Robust-Efficacy-in-Combination-with-Azacitidine-in-AML.html
https://endpts.com/servier-expands-tibsovo-label-with-first-combination-ok-in-a-rare-form-of-aml/
https://www.asiaone.com/business/servier-announces-fda-approval-tibsovo-ivosidenib-tablets-combination-azacitidine-patients
https://endpts.com/bristol-myers-dusts-off-an-old-celgene-chemotherapy-for-use-in-children-with-a-rare-blood-cancer/
https://www.prnewswire.com/news-releases/phase-3-agile-data-of-tibsovo-ivosidenib-tablets-in-combination-with-azacitidine-for-patients-with-previously-untreated-idh1-mutated-acute-myeloid-leukemia-published-in-the-new-england-journal-of-medicine-301529694.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-02-2022-1646291076.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211549
https://endpts.com/in-a-setback-fda-orders-gilead-to-hit-the-brakes-on-their-late-stage-5b-cancer-play/
https://www.fiercepharma.com/pharma/astellas-aml-drug-xospata-failed-its-trial-but-further-analysis-shows-it-benefited-some
https://ir.alxoncology.com/news-releases/news-release-details/alx-oncology-announces-initial-data-aspen-02-ongoing-phase-1-2
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-azacitidine-1637387689.pdf
https://endpts.com/fda-orders-clinical-hold-on-apreas-p53-reactivator-as-struggling-biotech-pledges-to-address-safety-concerns/
https://www.globenewswire.com/news-release/2021/07/06/2258077/33016/en/Trillium-Therapeutics-Announces-Dosing-of-First-Patient-in-Phase-1b-2-Study-of-TTI-622-in-Combination-With-Azacitidine-and-Venetoclax-in-TP53-Wild-Type-Acute-Myeloid-Leukemia.html
https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Onureg-azacitidine-tablets-as-Frontline-Oral-Maintenance-Therapy-for-Adults-with-Acute-Myeloid-Leukemia/default.aspx
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-december-16-2020-1608097779.pdf
https://www.newswire.ca/news-releases/health-canada-approves-venclexta-r-venetoclax-in-combination-with-azacitidine-or-low-dose-cytarabine-for-untreated-acute-myeloid-leukemia-aml--828572672.html
https://www.businesswire.com/news/home/20201207005856/en/Bristol-Myers-Squibb-Presents-Analyses-from-Pivotal-QUAZAR%C2%AE-AML-001-Study-of-Onureg%C2%AE-azacitidine-tablets-CC-486-in-Adults-with-Acute-Myeloid-Leukemia-in-First-Remission
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212128
http://www.globenewswire.com/news-release/2020/10/28/2115787/0/en/ALX-Oncology-Announces-First-Patient-Dosed-in-ASPEN-02-a-Phase-1-2-Study-of-ALX148-in-Combination-with-Azacitidine-in-Patients-with-Myelodysplastic-Syndrome.html
https://www.hikma.com/newsroom/article-i4901-hikma-launches-azacitidine-for-injection/#:~:text=London%2C%2010%20September%2C%202020%20%E2%80%93,affiliate%2C%20Hikma%20Pharmaceuticals%20USA%20Inc.
https://www.fiercepharma.com/marketing/bristol-myers-squibb-s-decade-old-vidaza-goes-oral-fda-nod-for-onureg-aml
http://www.pharmatimes.com/news/bms_bags_us_approval_for_onureg_1347617
http://www.globenewswire.com/news-release/2020/06/12/2047406/0/en/ORYZON-Presents-New-Phase-II-Iadademstat-Efficacy-Data-in-AML-at-EHA-2020.html
Market Place
Share 
